Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
about
An overview of cutaneous T cell lymphomasAddressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesT-cell lymphomas, a challenging disease: types, treatments, and future.Unique Presentation of Leukemic Cutaneous CD3/TCR- Phenotype T-Cell Lymphoma with Complete Remission after Allogeneic Stem Cell Transplantation.Mycosis Fungoides of the Oral Cavity: Fungating Tumor Successfully Treated with Electron Beam Radiation and Maintenance Bexarotene.Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeoverLangerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease.Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas.Antiproliferative effects of TSA, PXD‑101 and MS‑275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity.AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia.A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome.Monoclonal antibodies against cutaneous T-cell lymphomas.Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndromeSingle-cell heterogeneity in Sézary syndrome
P2860
Q26740306-93B77A98-0C55-42A9-8D19-8B22D1981013Q28074716-85145FBD-7892-41E4-83EC-14F74E9699E4Q30244553-3D2F8D15-CF8E-4A77-AC0D-1CCE11A07FE1Q33716514-3B5EF3D5-6A79-4046-8061-74A047567BD3Q37542591-071F70EE-BEAF-4DE4-A85A-E62B79680420Q37723390-0304C0B7-74CF-4143-916A-E2BCCF1DC13DQ38892071-537EF2AD-5FAF-4C64-A1FF-90A927D58F3FQ47122404-45D32A68-8789-4694-AE91-C42E09428F11Q47610009-1564EFF9-EC03-4E7B-9905-0C04CADB8D38Q47836540-9BA08FDF-C2B0-47B1-85F9-37F9E650D75CQ50101634-F053B4D3-6588-40B8-8715-823DD0613B11Q51484852-449CD933-0D6A-42F9-BE7C-760E66F92833Q51803389-4CB756AA-F2AA-4F17-B091-867B7F934A38Q57117878-AAAB6E07-B043-4DFA-8EF8-F21D56F4E239Q58712956-5CCED61A-F61F-445D-A943-34D546DEFC6D
P2860
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
@ast
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
@en
type
label
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
@ast
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
@en
prefLabel
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
@ast
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
@en
P2860
P356
P1476
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
@en
P2093
Ryan A Wilcox
P2860
P304
P356
10.1002/AJH.24233
P577
2015-11-26T00:00:00Z